Investors

Press Releases

ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City

July 17, 2019

Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the…

Read more

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

July 17, 2019

Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs

July 17, 2019

Geneva, Switzerland and Boston, MA – July 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more

ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna

June 21, 2019

ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna   Geneva,…

Read more

ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes

June 4, 2019

Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

May 16, 2019

Geneva, Switzerland and Boston, MA – May 16, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva Reports First Quarter 2019 Financial Results

May 9, 2019

2019 Phase 3 Data Readouts on track for nolasiban in IVF and linzagolix in uterine fibroids; MAA submission for nolasiban…

Read more

ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

May 9, 2019

Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019

May 8, 2019

Geneva, Switzerland and Boston, MA – May 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain

May 3, 2019

Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.